under investigation.
Platelet function is affected by changes in lipid metabolism (Nord0y 1976) . It is therefore interesting that the use of another hypolipidemic agent, clofibrate, has been associated with several hemostatic alterations including prolongation of bleeding time in man (O'Brien & Heywood 1966) and in the mouse (Herrmann 1973) ; decrease in the adhesiveness of blood platelets (Carson et al. 1963 , O'Reilly et al. 1972 ; inhibitory effects on adrenaline-induced platelet aggregation in normal subjects (O'Reilly et al. 1972) , and normalization of the exaggerated ADP-induced platelet aggregation in patients with type II hyperlipidxmia (Carvalho et al. 1974) . Clofibrate may also affect the coagulation system by temporarily increasing fibrinolytic activity and reducing fibrinogen levels (Chakrabarti et al. 1968) , and it augments the effect of oral anticoagulants (Oliver et al. 1963) . In hyperbetalipoproteineemia it normalizes the increased platelet factor-3 availability after ADP exposure (Nord0y & R0dset 1971) .
This pilot study is being carried out to find out whether gemfibrozil affects hemostatic parameters. Several tests of blood coagulation and platelet function were used in patients who were motivated by the hypolipidwmic action of the drug. The preliminary results are reported here.
MATERIAL AND METHODS

Patients
Ten patients with a previous history of hyperlipoproteinaemia were selected for the study. All were volunteers who understood the nature of-the trial. These 9 men and 1 woman ranged in age from 29 to 54. On entry to the study they had either a cholesterol level above 7.7 mmol/l or a triglyceride level above 1.7 mmol/l.
Medical and dietary history, physical and hmmatological examinations, including estimation of the main plasma lipid fractions, were carried out. None of the subjects was receiving lipid lowering agents during the six weeks before the trial, or acetylsalicylic acid in any form or any other drug known to affect platelet function, Dr V P 0 Rasi during the seven days before the platelet functions were studied. No dietary changes were made during the experimental period.
The patients were evaluated hmmostatically twice before treatment with the active agent. The means of these results were used as reference later in the study, and each subject served as her/ his own control. After the screening period, the patients were treated with gemfibrozil, 800 mg daily for four weeks, and the hemostatic and h&matological evaluation was repeated. The study is continuing, and the examinations will be repeated after eight weeks of treatment with a daily dose of 1600 mg of gemfibrozil.
Blood-collecting andProcessing Venous blood was drawn after an overnight fast, and 10-12 h after the last dose of the drug. Using a double-syringe technique, 10 ml of blood was taken into a plastic syringe and used without delay for the retention test. For aggregometry and platelet factor-3 (PF-3) activity studies, blood was collected in 0.106 M disodium citrate solution (9 v blood to 1 v anticoagulant). Platelet-rich plasma was prepared by centrifuging at 180 gravities for eight min at room temperature, and diluted with freshly prepared platelet-poor plasma from the same subject to a final concentration of 200 x 0I platelets/,ul. Platelet-poor plasma was obtained by recentrifugation of the platelet-rich plasma at 1800 gravities for 10 min. For coagulation studies, blood was taken in 0.1 M disodium oxalate (9 v blood to 1 v anticoagulant), centrifuged to platelet-poor plasma as described for citrated plasma and recentrifuged at 20,000 gravities for 30 min at +4°C. This platelet-free plasma was stored at -20°C before use.
Platelet Function Tests
Factor VIII activity was assayed by the kaolin-Platelet counts were measured by phase contrast activated partial thromboplastin time usingmicroscopy on whole blood (Bjorkman 1959) (Mielke et al. 1969 ). poor oxalate plasma. Platelet retention (adhesiveness) to glass beads was measured by a slight modification of the Hellem II RESULTS Method (Hellem 1970) . In this procedure, blood All patients were in good physical condition drawn without anticoagulant was passed through during the investigation. No side effects appeared, a standard glass bead column at the rate of 5.7 and adherence to the study was complete. ml/min. The columns were made of PVC-plastic tubing, bore 3 mm, filled with 1.3 g of glass beads Lipid Studies (Reflex Perlen 31/9, Dragon Werk, Bayreuth). All the patients had evidence of hyperlipoprotein-The delay between drawing of blood and initiammia when entering the study. Three of them tion of flow through the column was 10-12 sec. developed normal lipid values during the screen-Platelet retention is expressed as the percentage ing period when on placebo treatment, but were of platelets retained in the glass bead column. not excluded from the study. Treatment with Platelet aggregation was performed according to gemfibrozil markedly lowered both the mean the method of Born (1962) with a Born Mk III cholesterol and the mean triglyceride level, from Aggregometer equipped with a strip chart 8.1 to 6.5 mmol/l and from 2.5 to 1.8 mmol/l. recorder, by estimating changes in optical transmission of citrated plasma at 37°C with a con-Heematological Studies centration of 200 x I03 platelets/pi. In I ml No adverse changes were observed in routine aliquots, aggregation was observed under con-hoematology (erythrocyte sedimentation rate, tinuous stirring after the addition of adenosine hkmoglobin, hmmatocrit, WBC and differential diphosphate (ADP, Sigma, 1.0 x 10-6M and 3.0 x white cell count), blood chemistry (SGPT, 10-IM, final concentration); adrenaline (Medica, alkaline phosphatase, bilirubin) or in protein, 1.3 x 10-6fM and 5.0 x 10-6M, final concentration) ketones or glucose in analysis of urine, bile or and bovine tendon collagen (Sigma, 5 ,ul and 20 pl. blood. of standardized suspension). The rate of aggregation (which refers to optical transmission change/ Platelet Function Studies min) was measured as the tangent of the maximum The platelet count and the bleeding time remained slope of the aggregation curve. The degree of unchanged from pretreatment values during aggregation was measured 5 min after addition of gemfibrozil treatment (Table 1) . Platelet retention aggregating substance by the percentage change to the glass bead column decreased significantly in light transmission, with the transmission for (P<0.01, Wilcoxon test for pair differences). A platelet poor plasma arbitrarily set as 100% and decrease was seen in every patient. that for platelet rich plasma at 0%. All measure-ADP-induced, adrenaline-induced or collagenments were made within 2 h of the time blood was induced platelet aggregation were not markedly withdrawn by venepuncture. altered after gemfibrozil administration, but both the degree and the rate of aggregation showed a Blood Coagulation Tests slightly decreasing trend (Table 2) . Activated partial thromboplastin time of plasma Compared with the pretreatment mean value, was performed as described by Proctor & unchanged PF-3 activity was found after gem-Rapaport (1961) . fibrozil treatment (Table 3) . Following exposure The P and P method (Owren & Aas 1951) was to ADP, the post-treatment platelets showed a used to evaluate the prothrombin complex.
small decrease in PF-3 availability. The difference Thrombin clotting time of plasma was done by a is statistically significant (P<0.05, Student's modification of the method of Vermylen & t-test for paired means). PF-3 availability after Verstraete (1961) . The thrombin used (Toposta-incubation with kaolin or after freezing and cine, Roche) was reconstituted in 0.15 M NaCl so thawing did not differ in the two groups. that a clotting time of about 20 sec was obtained with pooled normal plasma.
Coagulation Studies Antithrombin III was quantitated immuno-As shown in Table 1 , no marked alteration from chemically by the single radial immunodiffusion pretreatment values occurred for either the technique (Mancini et al. 1965) using com-activated partial thromboplastin time, the P and mercial antisera (Behringwerke AG). P test, thrombin clotting time, factor VIII or ethanol gelation test. Antithrombin III showed a slight increase. All the tests were made with controls of normal pooled plasma and the results obtained for patients lay well within normal ranges.
DISCUSSION
The administration of gemfibrozil 800 mg/day for four weeks markedly reduced both the mean cholesterol level and the mean triglyceride level of the patients. Our preliminary results show a concomitant significant reduction of platelet retention to glass bead columns. Platelet aggregometry showed a uniform slightly decreasing trend in the responses to aggregation induced by ADP, adrenaline and collagen. These changes were not, however, reflected in the overall measure of the hemostatic role of platelets, i.e. bleeding time, which remained at the pretreatment level.
These findings closely resemble those obtained by O'Reilly et al. (1972) , who administered clofibrate to normal subjects.
Our results show decreased PF-3 availability after exposure to ADP in the post-treatment platelets. Nord0y and R0dset (1971) found increased PF-3 activity and increased PF-3 availability after ADP exposure in patients with hyperbetalipoproteinemia. Both changes were normalized after treatment with nicotinic acid and also with clofibrate.
Gemfibrozil had no marked effect on the coagulation mechanism, measured by the activated partial thromboplastin time, P and P test, thrombin clotting time, factor VIII, ethanol gelation test or antithrombin III assay.
Because of the design of the study, the results cannot be used to judge whether the parameters studied were normal or not in the patients. Nor do they tell whether the effects of gemfibrozil in hyperlipidemic patients differ from those in normal subjects. But it is concluded that gemfibrozil affects hemostatic parameters, and it remains to be shown whether these effects are maintained during prolonged use of the drug and also whether there is any dose-related correlation in the response to the drug. As the hemostatic changes caused by gemfibrozil closely resemble those described for clofibrate, precautions with regard to the administration of the drug simultaneously with anticoagulants may be relevant (Oliver et al. 1963) , and this aspect also deserves attention.
